Taysha Gene Therapies, Inc. Stock Price, News & Analysis

Taysha Gene Therapies (Nasdaq: TSHA) announced the appointment of Mary Newman as Chief Development Officer, enhancing its leadership team. Newman, with over 30 years in regulatory affairs and research within biotechnology, will manage program and portfolio operations, reporting to Chief Medical Officer Suyash Prasad. Her prior experience includes roles at Astellas Gene Therapies and BioMarin Pharmaceutical, where she contributed to significant drug approvals. CEO RA Session II emphasized Newman’s role in advancing Taysha’s ambitious pipeline for monogenic CNS disorders.

Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in two virtual events: the 2021 RBC Capital Markets Global Healthcare Conference on May 19 at 3:05 PM ET and the Oppenheimer Rare & Orphan Disease Summit on May 21 at 4:35 PM ET. The discussions will involve key executives including RA Session II, Dr. Suyash Prasad, and Kamran Alam. Webcasts will be available in the Events & Media section of their corporate website for 60 days after the events.

Taysha Gene Therapies (Nasdaq: TSHA) reported Q1 2021 financial results, noting a net loss of $32 million, or $0.87 per share, compared to $5.4 million, or $0.50 per share in Q1 2020. The company acquired TSHA-120 for GAN, showing promising clinical data with 14 patients dosed. Preclinical results for TSHA-102 in Rett syndrome demonstrated a significant 56% survival extension in knockout mice. Taysha plans to advance five programs into Phase 1/2 trials by year-end and aims to submit an IND application for TSHA-102 by then. The company has $228.7 million in cash, expected to support operations into 2023.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) has published promising preclinical data for TSHA-102 in treating Rett syndrome, featured in the renowned journal Brain. TSHA-102 employs a novel self-regulatory mechanism that enables controlled expression of MECP2, which is critical for avoiding overexpression toxicity. In studies, TSHA-102 extended the survival of knockout mice by 56%, contrasting with unregulated treatments that showed unacceptable toxicity. The company plans to file an IND/CTA for TSHA-102 in the second half of the year and initiate a Phase 1/2 trial by year-end 2021, addressing a significant need for 25,000 patients.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the presentation of promising preclinical data at the 24th Annual Meeting of the American Society of Gene & Cell Therapy. Key highlights include positive results for TSHA-104 in treating SURF1-associated Leigh syndrome and TSHA-105 for SLC13A5 deficiency. Both therapies showed significant efficacy in enhancing neurological functions in mouse models. Taysha plans to file an IND/CTA for TSHA-104 later this year and continue progressing TSHA-105 towards clinical trials.

Taysha Gene Therapies (Nasdaq: TSHA) has announced a conference call for a corporate update and to report its financial results for Q1 2021, scheduled for May 11, 2021, at 8:00 AM ET. The company focuses on AAV-based gene therapies for monogenic CNS diseases and is dedicated to translating scientific advancements into curative medicines. Taysha aims to leverage its partnership with UT Southwestern Gene Therapy Program to enhance its gene therapy pipeline, addressing both rare and large patient populations.

Taysha Gene Therapies (Nasdaq: TSHA) announced new preclinical data showcasing advancements in its gene therapy pipeline, emphasizing TSHA-113, which reduced tau expression in mouse models for tauopathies. Taysha plans to advance five programs into IND/CTA-enabling studies and file an IND for one candidate by year-end 2021. The company reported a significant commercial opportunity for therapies targeting various CNS diseases affecting large patient populations, including Alzheimer's, with a combined estimate of over 6 million Americans affected.

Taysha Gene Therapies (Nasdaq: TSHA) has acquired exclusive global rights to TSHA-120, a clinical-stage AAV9 gene therapy for giant axonal neuropathy (GAN). This therapy is currently in an NIH-led clinical trial, having received FDA designations as a rare pediatric disease and orphan drug. TSHA-120 shows promise in halting disease progression, with significant improvements in motor function observed in treated patients. The potential market opportunity is over $2 billion for approximately 2,400 patients in the U.S. and Europe. Taysha plans to engage with regulatory agencies to expedite the approval process.

Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in two upcoming virtual conferences: the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 10:15 am ET and the Chardan 5th Annual Manufacturing Summit on April 26, 2021, at 1:00 pm ET. Both events will feature fireside chats led by key executives, including the President and CEO, RA Session II, along with others from the company.

Webcasts of these events can be accessed on the Taysha corporate website, with archived versions available for 60 days.